BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38582399)

  • 1. Clinical Validation of a Targeted Next-Generation Sequencing Panel for Lymphoid Malignancies.
    Artymiuk CJ; Basu S; Koganti T; Tandale P; Balan J; Dina MA; Barr Fritcher EG; Wu X; Ashworth T; He R; Viswanatha DS
    J Mol Diagn; 2024 Jul; 26(7):583-598. PubMed ID: 38582399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies.
    Navrkalova V; Plevova K; Hynst J; Pal K; Mareckova A; Reigl T; Jelinkova H; Vrzalova Z; Stranska K; Pavlova S; Panovska A; Janikova A; Doubek M; Kotaskova J; Pospisilova S
    J Mol Diagn; 2021 Aug; 23(8):959-974. PubMed ID: 34082072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.
    Hung SS; Meissner B; Chavez EA; Ben-Neriah S; Ennishi D; Jones MR; Shulha HP; Chan FC; Boyle M; Kridel R; Gascoyne RD; Mungall AJ; Marra MA; Scott DW; Connors JM; Steidl C
    J Mol Diagn; 2018 Mar; 20(2):203-214. PubMed ID: 29429887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
    Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
    Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer.
    Wang SR; Malik S; Tan IB; Chan YS; Hoi Q; Ow JL; He CZ; Ching CE; Poh DYS; Seah HM; Cheung KHT; Perumal D; Devasia AG; Pan L; Ang S; Lee SE; Ten R; Chua C; Tan DSW; Qu JZZ; Bylstra YM; Lim L; Lezhava A; Ng PC; Wong CW; Lim T; Tan P
    J Mol Diagn; 2016 May; 18(3):416-424. PubMed ID: 26970585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OncoKids: A Comprehensive Next-Generation Sequencing Panel for Pediatric Malignancies.
    Hiemenz MC; Ostrow DG; Busse TM; Buckley J; Maglinte DT; Bootwalla M; Done J; Ji J; Raca G; Ryutov A; Xu X; Zhen CJ; Conroy JM; Hazard FK; Deignan JL; Rogers BB; Treece AL; Parham DM; Gai X; Judkins AR; Triche TJ; Biegel JA
    J Mol Diagn; 2018 Nov; 20(6):765-776. PubMed ID: 30138724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens.
    Haley L; Parimi V; Jiang L; Pallavajjala A; Hardy M; Yonescu R; Morsberger L; Stinnett V; Long P; Zou YS; Gocke CD
    J Mol Diagn; 2021 Oct; 23(10):1343-1358. PubMed ID: 34358677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies.
    Guillermin Y; Lopez J; Chabane K; Hayette S; Bardel C; Salles G; Sujobert P; Huet S
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29677173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.
    Lorenz J; Rothhammer-Hampl T; Zoubaa S; Bumes E; Pukrop T; Kölbl O; Corbacioglu S; Schmidt NO; Proescholdt M; Hau P; Riemenschneider MJ
    Acta Neuropathol Commun; 2020 Aug; 8(1):124. PubMed ID: 32758285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
    Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
    Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
    Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
    BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine learning random forest for predicting oncosomatic variant NGS analysis.
    Pellegrino E; Jacques C; Beaufils N; Nanni I; Carlioz A; Metellus P; Ouafik L
    Sci Rep; 2021 Nov; 11(1):21820. PubMed ID: 34750410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies.
    Kim H; Yun JW; Lee ST; Kim HJ; Kim SH; Kim JW;
    Ann Lab Med; 2019 Nov; 39(6):515-523. PubMed ID: 31240878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted massively parallel sequencing in the management of cytogenetically normal lymphoid malignancies.
    Ikbal Atli E; Gurkan H; Atli E; Yalcintepe S; Demir S; Eker D; Kalkan R; Muzaffer Demir A
    J BUON; 2021; 26(4):1540-1548. PubMed ID: 34565017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.